Answers are grounded in this paper and cite their sources.
Our group previously discovered that the levels of branched-chain amino acids (BCAAs) increased in the perihematomal tissue of mice with intracerebral hemorrhage (ICH); however, the cause and biological significance of this remain unclear. Here, we determined BCAA levels and changes in the expression levels of proteins responsible for BCAA breakdown at different time points post-ICH. We then treated ICH mice with the branched-chain α-ketoacid dehydrogenase complex (BCKDH) kinase inhibitor BT2 and investigated its influence on ICH-induced neurological deficits, cell death, and the serum metabolic profile. ICH resulted in the accumulation of BCAAs, increased expression levels of BCKDH kinase and phosphorylated BCKDH, as well as downregulated branched-chain aminotransferase expression levels. BT2 reduced the accumulation of BCAAs and cell death, consequently exerting neuroprotective effects. BT2 treatment resulted in an altered metabolic profile of serum after ICH mainly by effects on amino acid metabolism, including but not limited to BCAAs. This may constitute the metabolic basis for its neuroprotective effect. In conclusion, BT2 accelerates the breakdown of BCAAs after ICH and reduces cell death and neurological deficits; thus, BCAA metabolism represents a potential therapeutic target for ICH.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: